United States Proteomics Market

United States Proteomics Market Size and Share:

The United States proteomics market size was valued at USD 11.43 Billion in 2024. Looking forward, the market is expected to reach USD 41.78 Billion by 2033, exhibiting a CAGR of 14.72% during 2025-2033. The market is witnessing robust growth driven by advancements in mass spectrometry, increasing research in personalized medicine, and the growing incidence of chronic diseases. Supportive government funding and expanding pharmaceutical research and development (R&D) further contribute to market expansion. These developments collectively strengthen the United States proteomics market share.

One of the primary drivers is the increasing focus on precision medicine and personalized healthcare, which relies heavily on protein profiling to identify disease biomarkers and tailor treatments accordingly. This trend is supported by significant investments from both public and private sectors into biomedical research, particularly initiatives by the National Institutes of Health (NIH) and other government agencies. Additionally, advancements in mass spectrometry, chromatography, and protein microarrays have significantly enhanced the accuracy, sensitivity, and throughput of proteomic analyses, making these tools more viable for clinical applications and drug discovery. The increasing occurrence of chronic diseases like diabetes, cancer, and cardiovascular disorders has also intensified the demand for advanced diagnostic and prognostic tools, further propelling the market. For instance, in January 2025, Sapient, a prominent name in multi-omics research, joined forces with Alamar Biosciences, renowned for its cutting-edge, ultra-sensitive, and multiplex immunoassay technologies. Through this collaboration, Sapient is expanding its targeted proteomics offerings by incorporating high-sensitivity assays for cytokines, chemokines, and neuroinflammatory markers.

The United States proteomics market growth is also driven by the growth of the pharmaceutical and biotechnology industries in the US, which has led to increased research and development (R&D) activities focused on novel therapeutics and biomarker discovery. Collaborations between academic institutions and industry players are also playing a crucial role in accelerating innovation. For instance, in January 2024, Creative Proteomics, a prominent name in proteomic research services, broadened its analytical offerings by launching its Label-free Quantification Service. This cutting-edge technique enables comprehensive protein measurement across complex samples without relying on chemical or radioactive labeling. The advancement marks a significant step toward more efficient, scalable, and safer quantification methods in proteomics. Moreover, the expanding adoption of artificial intelligence and data analytics in proteomics for deeper biological insights is boosting the efficiency of protein-based research, supporting the continued expansion of the market.

United States Proteomics Market Trends:

Surging Demand for Personalized Medicine and Precision Healthcare

The growing emphasis on personalized medicine is a primary driver of the US proteomics market. As healthcare shifts toward individualized treatment plans based on genetic and protein-level information, proteomics plays a vital role in identifying disease biomarkers and understanding patient-specific responses to therapies. This demand is especially strong in oncology, cardiology, and neurology, where precise protein expression profiles aid in diagnosis and treatment. For instance, in May 2023, Proteomics International Laboratories Ltd entered into an exclusive licensing agreement with Sonic Healthcare USA, a subsidiary of Sonic Healthcare Ltd, to support the deployment and commercialization of its PromarkerD diagnostic test for diabetic kidney disease across the United States. Proteomic technologies enable clinicians to detect subtle molecular changes, improving patient outcomes through early intervention. The United States, with its advanced healthcare infrastructure and investment in biotech research and development (R&D), is at the forefront of integrating proteomics into clinical decision-making, which is further creating a positive United States proteomics market outlook.

Technological Advancements in Mass Spectrometry and Bioinformatics

Continuous innovation in mass spectrometry, chromatography, and computational biology is significantly enhancing the capabilities of proteomics in the US market. Modern instruments now offer greater resolution, sensitivity, and throughput, allowing for more comprehensive and accurate protein analysis. Coupled with advanced bioinformatics tools, researchers can process massive data sets, identify complex protein interactions, and interpret functional implications with greater precision. The integration of AI and machine learning further strengthens data analysis, aiding in faster and more accurate biomarker discovery. These technological breakthroughs are expanding applications in drug discovery, clinical diagnostics, and translational research, making proteomics more accessible and practical. According to the United States proteomics market analysis, this wave of innovation is encouraging greater investment and adoption across pharmaceutical, academic, and clinical settings. For instance, in April 2024, Biognosys, a prominent name in mass spectrometry-driven proteomics, entered a strategic alliance with Alamar Biosciences, Inc., a pioneer in precision proteomics focused on early disease detection. This collaboration seeks to accelerate scientific breakthroughs in identifying biofluid-based proteomic biomarkers. The collaboration combines Alamar's cutting-edge multiplex immunoassay technologies with Biognosys' expertise in objective proteome exploration utilizing data-independent acquisition mass spectrometry (DIA-MS), resulting in a potent synergy to improve biomarker discovery and spur industry innovation.

Government and Private Sector Investment in Biomedical Research

The substantial public and private funding dedicated to life sciences research is acting as a major United States proteomics market trend. Initiatives by organizations such as the National Institutes of Health (NIH) and the Human Proteome Organization (HUPO) support large-scale proteomic studies and infrastructure development. Simultaneously, biotech and pharmaceutical companies are investing in proteomics to accelerate drug development and reduce research and development (R&D) timelines. Accordingly, in 2024, Syncell raised USD 15 Million in Series A funding, bringing total investment to USD 30 Million. The company will expand global commercialization of its Microscoop platform for spatial proteomics, aiming to support research in oncology, neurodegenerative diseases, and drug discovery. Collaborative efforts between academia, industry, and government are fostering innovation, data sharing, and standardization in proteomic workflows. Additionally, public health priorities, including pandemic preparedness and chronic disease management, have elevated the strategic importance of proteomics in national biomedical agendas. This strong financial and policy support creates a conducive environment for innovation, adoption, and long-term market expansion.

United States Proteomics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the United States proteomics market, along with forecasts at the regional, and country levels from 2025-2033. The market has been categorized based on analysis type, component type, technology, application, and end user.

Analysis by Analysis Type:

• Structural Proteomics
• Functional Proteomics
• Protein Expression Proteomics

Functional proteomics stand as the largest analysis type in 2024, holding 47.6% of the market due to its ability to directly evaluate protein function, interactions, and modifications within biological contexts, making it indispensable for drug discovery, biomarker identification, and precision medicine. US. leadership in proteomics is further driven by substantial NIH funding and industry investment in targeted therapies, enabling integration of functional proteomics into clinical diagnostics and pharmaceutical development. Moreover, advanced bioinformatics tools and high-throughput mass spectrometry capabilities support comprehensive data analysis, fueling adoption across both academic and biotech sectors. The confluence of scientific utility, financial backing, and analytical power cements functional proteomics as the market's leading segment

Analysis by Component Type:

• Core Proteomics Services
• Bioinformatics Software and Related Services

Core proteomics services are expected to hold the largest share in the United States proteomics market due to their widespread use in academic research, pharmaceutical development, and clinical diagnostics. These services offer standardized, high-throughput analysis of proteins, including identification, quantification, and post-translational modifications. Many institutions and biotech firms prefer outsourcing to specialized service providers to reduce infrastructure costs and access cutting-edge technologies. The growing need for biomarker discovery, drug target validation, and personalized medicine applications further drives demand. Additionally, increasing collaborations between research institutions and core facilities support the segment’s dominance by enabling reliable, scalable, and efficient proteomic research workflows.

Bioinformatics software and related services are anticipated to fuel the US proteomics market demand owing to the massive volume and complexity of proteomic data. Advanced tools are essential for analyzing, interpreting, and visualizing large datasets generated through techniques like mass spectrometry and protein microarrays. The integration of artificial intelligence and machine learning enhances data accuracy, functional annotation, and predictive modeling. With the expansion of personalized medicine and systems biology, there’s a rising demand for precise protein mapping and interaction networks. Additionally, ongoing software innovation and cloud-based platforms are making bioinformatics tools more accessible and scalable, solidifying their critical role in proteomics research and commercialization.

Analysis by Technology:

• Spectroscopy
• Chromatography
• Electrophoresis
• Protein Microarrays
• X-Ray Crystallography
• Surface Plasmon Resonance
• Others

Spectroscopy stand as the largest share in 2024, holding 41.9% of the market due to its central role in accurate protein identification, structural analysis, and quantification. Techniques such as mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy offer high sensitivity, resolution, and scalability, making them indispensable for proteomic research and clinical diagnostics. These methods support biomarker discovery, disease profiling, and drug development with unparalleled precision. The widespread availability of advanced instruments, along with robust research and development (R&D) funding and technological innovation in the U.S., further accelerates adoption. Spectroscopy’s versatility, reliability, and integration into high-throughput platforms solidify its dominance in the country’s proteomics landscape.

Analysis by Application:

• Protein Expression Profiling
• Proteome Mining
• Post-Translational Modifications

Protein expression profiling is expected to hold a significant share in the market due to its crucial role in understanding disease mechanisms, cellular processes, and therapeutic targets. By analyzing protein expression across various biological states or conditions, researchers gain valuable insights into disease progression and treatment efficacy. The increasing demand for personalized medicine, oncology research, and drug discovery is driving widespread adoption. Additionally, the availability of high-throughput platforms and automated tools enhances data accuracy and reproducibility. Strong support from academic institutions, biotech companies, and healthcare providers further positions protein expression profiling as a cornerstone of modern biomedical research.

Proteome mining is anticipated to hold a large market share as it enables comprehensive exploration of the entire protein landscape within a biological system. This technique is vital for identifying novel biomarkers, drug targets, and functional proteins relevant to complex diseases like cancer and neurodegeneration. In the US, heavy investment in systems biology, precision medicine, and biotechnology research and development (R&D) is fueling demand for in-depth proteomic mapping. Proteome mining also benefits from advances in mass spectrometry, machine learning, and bioinformatics, which improve data resolution and interpretation. Its critical application in uncovering new molecular pathways ensures its prominence in both academic and industrial proteomics efforts.

Post-translational modifications (PTMs) hold a leading share in the market because they play a central role in regulating protein function, localization, and interaction. PTMs such as phosphorylation, glycosylation, and ubiquitination are key to understanding signaling pathways, immune responses, and disease states. Advanced analytical technologies now enable high-throughput and precise detection of PTMs, making them invaluable in both basic research and clinical diagnostics. The growing interest in cancer biology, autoimmune diseases, and epigenetics is further boosting demand. With pharmaceutical companies increasingly targeting PTM-related proteins, this segment has become a focal point for therapeutic development and biomarker discovery across the US market.

Analysis by End User:

• Clinical Diagnostic Laboratories
• Research Organizations (Drug Discovery)
• Others

Clinical diagnostic laboratories lead the market with 48.9% of market share in 2024 because they serve as indispensable providers of protein-based biomarker testing for disease diagnosis, prognosis, and therapeutic monitoring. These labs are equipped with advanced mass spectrometry systems, standardized protocols, and rigorous quality standards—ensuring high reliability and reproducibility in clinical-grade analyses. As demand for personalized medicine grows, proteomics-driven diagnostics offer clinicians precise insights into patient conditions and treatment responses. Moreover, partnerships between diagnostics giants (e.g., LabCorp, Quest) and proteomics technology firms streamline service delivery, fueling adoption. Supported by research funding and regulatory frameworks, these labs establish themselves as primary users of clinical proteomics services and instruments.

Regional Analysis:

• Northeast
• Midwest
• South
• West

The Northeast US leads in proteomics innovation due to its concentration of world-class research universities, teaching hospitals, and biotech firms, particularly in cities like Boston, New York, and Philadelphia. Institutions such as Harvard, MIT, and the Broad Institute heavily invest in protein-based research and personalized medicine. The region’s strong funding ecosystem—through NIH grants and venture capital—supports advanced proteomics tools and collaborations. With a focus on translational research and oncology, the Northeast drives high demand for protein biomarker discovery, mass spectrometry, and functional analysis, positioning it as a national leader in clinical proteomics and academic-industry partnerships.

The Midwest's proteomics market is driven by its robust pharmaceutical manufacturing base, large academic research institutions, and increasing investment in biotechnology. Home to institutions like the University of Michigan and Mayo Clinic, the region prioritizes protein research for chronic disease management and diagnostics. Agricultural biotechnology is also significant, where proteomics is used in crop and livestock improvements. The affordability of operating costs compared to coastal regions enables more research and development (R&D)-intensive startups to emerge. Additionally, government-backed innovation hubs and public-private partnerships are helping build strong infrastructure for biomedical and proteomic advancements, positioning the Midwest as a growing contributor to the national proteomics landscape.

The Southern US is experiencing rapid growth in the proteomics sector, fueled by rising healthcare demand, strong public health institutions, and an expanding biopharmaceutical presence. Cities like Houston, Atlanta, and Research Triangle Park in North Carolina host cutting-edge medical centers and life sciences clusters. The region’s focus on cancer research, metabolic diseases, and genomics supports proteomics applications in both diagnostics and therapeutic development. Additionally, lower cost of living and state-level incentives are attracting biotech firms and research labs. Academic institutions and industry players are increasingly collaborating on protein profiling, biomarker discovery, and clinical proteomics, driving growth across the South.

The Western US, particularly California, is a major driver of the proteomics market due to its leadership in biotech innovation, AI integration, and venture-backed research. Home to Silicon Valley and the San Diego biotech corridor, the region sees heavy investment in drug discovery, omics technologies, and computational biology. Institutions like Stanford and UC San Diego play key roles in translational proteomics. Tech-biotech convergence supports the development of bioinformatics tools, essential for high-throughput proteomic data analysis. Furthermore, the West’s emphasis on personalized medicine and startup-friendly ecosystem accelerates the commercialization of proteomics applications, making it one of the most dynamic regions for growth.

Competitive Landscape:

The United States proteomics market features a competitive landscape marked by the presence of major global players, innovative startups, and academic collaborations. Key companies such as Danaher Corporation, Thermo Fisher Scientific, Agilent Technologies, and Bruker Corporation lead the market with robust portfolios in mass spectrometry, protein analysis, and bioinformatics. Strategic partnerships, mergers, and investments in high-throughput technologies and AI-driven analytics are intensifying competition. Emerging firms are also gaining traction by offering niche solutions in protein quantification and biomarker discovery. The market’s competitive dynamics are driven by rapid technological advancements, increasing research and development (R&D) spending, and a growing demand for precision medicine, shaping the evolving landscape of the United States proteomics market.

The report provides a comprehensive analysis of the competitive landscape in the United States proteomics market with detailed profiles of all major companies.

Latest News and Developments:

• June 2025: SCIEX and Evosep announced a reseller agreement to co-sell SCIEX mass spectrometry systems with the Evosep Eno for standardized high-throughput proteomics. This collaboration improves throughput, sensitivity, and reproducibility, offering enhanced proteome coverage for large-scale studies in pharmaceutical and biotech research.
• June 2025: Thermo Fisher Scientific launched advanced solutions at ASMS 2025, including the Orbitrap Astral Zoom MS and Orbitrap Excedion Pro MS for proteomics and biopharma research. These instruments offer improved speed, sensitivity, and functionality, enhancing applications in drug development, disease research, and environmental studies.
• May 2025: Seer launched the Proteograph ONE Assay and SP200 Automation Instrument at ASMS 2025, enhancing throughput, efficiency, and scalability for mass spec-based proteomics. The new workflow processes over 1,000 samples weekly, reducing per-sample costs by 60%, and enabling large-scale biomarker discovery and longitudinal disease studies.
• May 2025: Bruker launched the timsOmni Mass Spectrometer, integrating timsTOF speed with Omnitrap functionality for advanced proteoform sequencing and post-translational modification identification. It offers unmatched flexibility, sensitivity, and deep sequence coverage, transforming disease research, biologics development, and bioprocessing QC with top-down sequencing and machine learning software.
• May 2025: Pictor established its U.S. headquarters in Carlsbad, California, backed by USD 5 Million in seed funding. The company’s flexible, cost-effective multiplex proteomics platform supports labs with affordable, high-throughput testing. Pictor's platform is positioned to meet growing healthcare demands and regulatory changes, enhancing diagnostic access and efficiency.
• February 2025: Ignite Proteomics, a subsidiary of IMAC Holdings, acquired PLA code 0249U for its proteomic breast cancer assay. This code, listed on the Medicare Clinical Laboratory Fee Schedule, enables reimbursement for the assay, which measures active protein activity in breast tumors, enhancing precision oncology and targeted therapies.
• January 2025: Quantum-Si launched the Platinum Pro, a next-generation benchtop protein sequencer offering streamlined user experience, flexible data analysis, and custom application development for proteomics research. The system, available for order, is designed to drive breakthroughs in protein analysis and is supported by a new partnership with Avantor.

United States Proteomics Market Report Scope:

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the United States proteomics market from 2019-2033.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the United States proteomics market.
• Porter's Five Forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the United States proteomics industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.